Oncotarget

Research Papers:

Molecular basis for the DNA damage induction and anticancer activity of asymmetrically substituted anthrapyridazone PDZ-7

Majus Misiak _, Mateusz Heldt, Marlena Szeligowska, Stefania Mazzini, Leonardo Scaglioni, Grzegorz J. Grabe, Marcin Serocki, Jan Lica, Marta Switalska, Joanna Wietrzyk, Giovanni L. Beretta, Paola Perego, Dominik Zietkowski, Maciej Baginski, Edward Borowski and Andrzej Skladanowski

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:105137-105154. https://doi.org/10.18632/oncotarget.21806

Metrics: PDF 486 views  |   HTML 1061 views  |   ?  


Abstract

Majus Misiak1, Mateusz Heldt1,*, Marlena Szeligowska1,*, Stefania Mazzini2, Leonardo Scaglioni2, Grzegorz J. Grabe3, Marcin Serocki1, Jan Lica1, Marta Switalska5, Joanna Wietrzyk5, Giovanni L. Beretta4, Paola Perego4, Dominik Zietkowski6, Maciej Baginski1, Edward Borowski1,6,** and Andrzej Skladanowski1

1Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland

2Department of Food, Environmental and Nutritional Sciences, Division of Chemistry and Molecular Biology, University of Milan, Milan, Italy

3Department of Medicine, Faculty of Medicine, Imperial College London, London, UK

4Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

5Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

6BS-154 sp. z o.o., Gdansk, Poland

*These authors have contributed equally to this work

**Prof. Edward Borowski passed away on August 17, 2016

Correspondence to:

Majus Misiak, email: majus.misiak@pg.gda.pl

Keywords: actin; anthraquinone; cell cycle; DNA repair; topoisomerase

Received: April 07, 2017     Accepted: September 23, 2017     Published: October 10, 2017

ABSTRACT

Anthrapyridazones, imino analogues of anthraquinone, constitute a family of compounds with remarkable anti-cancer activity. To date, over 20 derivatives were studied, of which most displayed nanomolar cytotoxicity towards broad spectrum of cancer cells, including breast, prostate and leukemic ones. BS-154, the most potent derivative, had IC50 values close to 1 nM, however, it was toxic in animal studies. Here, we characterize another anthrapyridazone, PDZ-7, which retains high cytotoxicity while being well tolerated in mice. PDZ-7 is also active in vivo against anthracycline-resistant tumor in a mouse xenograft model and induces DNA damage in proliferating cells, preferentially targeting cells in S and G2 phases of the cell cycle. Activation of Mre11-Rad50-Nbs1 (MRN) complex and phosphorylation of H2AX suggest double-stranded DNA breaks as a major consequence of PDZ-7 treatment. Consistent with this, PDZ-7 treatment blocked DNA synthesis and resulted in cell cycle arrest in late S and G2 phases. Analysis of topoisomerase IIα activity and isolation of the stabilized covalent topoisomerase IIα - DNA complex in the presence of PDZ-7 suggests that this compound is a topoisomerase IIα poison. Moreover, PDZ-7 interfered with actin polymerization, thereby implying its action as a dual inhibitor of processes critical for dividing cells. Using nuclear magnetic resonance (NMR) spectroscopy we show that PDZ-7 interacts with DNA double helix and quadruplex DNA structure. Taken together, our results suggest that PDZ-7 is a unique compound targeting actin cytoskeleton and DNA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21806